Inspired by the success of CD38 monoclonal antibodies, many preclinical studies on CAR‐T and CAR‐NK cell therapies targeting CD38 have been conducted and shown promising results in the treatment of MM, AML, B‐ALL, and B‐NHL.[28, 33, 40, 41, 42, 43] Clinical trials of CD38‐specific CAR‐T cells are in progress for the treatment of MM, AML, and B‐ALL. Here, CD38 is linked to non-Hodgkin lymphoma.